SCIENCE
Health Economics
Abstract. Health Economics studies the allocation, financing, production, consumption, and distribution of health and health-related goods under scarcity, uncertainty, incomplete information, and institutional constraints. The discipline encompasses health itself as an outcome, medical care as an input, insurance as a mechanism for transferring financial risk, public health as a domain of collective action, and health systems as complex arrangements of patients, providers, payers, governments, and producers. This monograph reconstructs the field's historical emergence, foundational economic models, empirical identification strategies, comparative institutions, pharmaceutical innovation, public health externalities, distributional questions, health technology assessment, and evolving global challenges. It integrates the original contributions of Arrow, Grossman, Fuchs, Preston, the RAND experiment, the Oregon randomized insurance studies, industrial organization, and contemporary WHO, OECD, and health economic evaluation standards. Formal sections explain health-capital dynamics, insurance and moral hazard, provider incentives, economic evaluation, budget constraints, and welfare accounting. The central analytical conclusion is that health policy must evaluate the joint consequences of health outcomes, financial protection, equity, real resource use, and institutional performance. These objectives are connected through identifiable mechanisms but cannot be represented adequately by any one expenditure or utilization statistic. The final synthesis is an interpretive integration of established research, without the proposal of a newly named theory or unverified empirical claims.
Keywords: Health economics; health capital; medical care; healthcare markets; health insurance; financial protection; adverse selection; moral hazard; provider incentives; health technology assessment; cost-effectiveness; QALY; DALY; universal health coverage; public health; health equity; pharmaceutical innovation; hospital competition; causal inference; health expenditure accounts; epidemiological transition; economic development
1. The Scientific Object and Boundaries of Health Economics
Health Economics is the scientific study of choices, constraints, exchanges, institutions, and distributions involving health and the means of producing it. Its central object contains at least five separable elements: health states valued by individuals and populations; the time and commodities that influence health; professional services that diagnose and treat illness; financing arrangements that redistribute risk and purchasing power; and political or organizational mechanisms that determine which services exist, where, and for whom. The disciplinary problem arises because societies must combine these elements while resources have competing uses. A hospital bed, nursing hour, preventive program, research laboratory, or unit of public revenue always has an opportunity cost.
The field belongs to the broader economics of welfare, uncertainty, industrial organization, public finance, labor, and development. Its distinctive analytical challenge is the simultaneous presence of biological uncertainty, heterogeneous preferences, professional information, emergency demand, insurance contracts, strong distributional concerns, and social spillovers. The classic analysis of uncertain medical care explains why ordinary complete-market assumptions are strained by the structure of this industry. The industrial-organization literature subsequently places insurer bargaining, hospital concentration, and treatment decisions inside the same economic inquiry.
Research must keep the outcome of health distinct from the observable consumption of services. An intervention can reduce emergency visits by preventing illness, or by obstructing necessary access; identical utilization statistics can describe opposing welfare effects. Increased expenditure may signal waste, treatment of previously unmet need, higher input prices, or genuine medical progress. Hence credible scientific analysis specifies a population, time horizon, counterfactual, cost perspective, health endpoint, and distributional objective. These distinctions provide the organizing logic of this monograph.
2. The Historical Formation of the Discipline
The origins of economic thinking about health extend to demography, poor relief, sanitation, mortality tables, occupational health, and the political economy of social insurance. Classical political economy asked how population, labor capacity, institutions, and living standards shape material prosperity. Nineteenth- and early twentieth-century improvements in water, nutrition, vaccination, epidemiological surveillance, and urban infrastructure demonstrated that population health depends upon the entire social environment. These historical developments cannot be collapsed into a linear story in which modern hospitals simply produced modern longevity.
The field gained a coherent modern research agenda when Kenneth Arrow's 1963 welfare analysis of medical care examined uncertainty, information, professional conduct, insurance, and the incompleteness of markets. Michael Grossman's 1972 health-capital model formalized individual demand for health as a jointly produced, depreciating stock. Victor Fuchs's studies of social choice and medical organization emphasized the allocation problem faced by every health system. Samuel Preston's 1975 income-mortality comparison demonstrated that historical shifts in life expectancy cannot be read solely from contemporary per-capita income. These research traditions established distinct but complementary questions about demand, institutions, social conditions, and mortality.
Randomized evidence later transformed the empirical side of the discipline. The 1970s RAND experiment, reported in the randomized cost-sharing study, estimated responses to medical prices, while the Oregon lottery produced a series of insurance studies with unusually transparent assignment. The maturation of cost-effectiveness analysis, economic evaluation foundations, provider competition research, national health accounts, and global health measurement widened the field into an international research program. Contemporary health economics combines structural models, causal designs, administrative data, ethical assessments, and transparent comparative measurement.
3. Health, Healthcare, Well-Being, and Scarcity
Health is a multidimensional state involving survival, physical and mental functioning, freedom from disabling symptoms, and capacity for valued activities. Healthcare is a set of professionally organized interventions that may change those states. This difference matters for both production theory and public policy. Diet, employment, education, clean water, safe housing, pollution, social networks, genetics, and random shocks also influence health, often outside the jurisdiction of hospitals and insurers. Research on social determinants documents the structural importance of living conditions and resource distribution.
Economic scarcity is the condition that a feasible intervention consumes resources that could generate benefits elsewhere. It does not establish a fixed ethically acceptable level of care. Rather, it requires explicit comparison of consequences at the margin. Providing a new treatment to one group may displace the training of nurses, maintenance of diagnostic equipment, or prevention among another group. Efficiency asks whether an allocation can generate more valued outcomes from available resources. Equity asks how those outcomes and burdens are distributed. Welfare analysis brings these questions together through a declared social objective.
The unit of analysis must be chosen carefully. A clinically effective intervention can be expensive per unit of health gain; a cost-saving intervention can have harmful distributional consequences; and an effective population policy can operate without a one-to-one patient transaction. WHO's health-system performance framework recognized that systems should be evaluated through more than expenditure. A scientific account therefore treats individual utility, population health, financial protection, responsiveness, and social priorities as measurable or deliberable components whose relative importance must be stated.
4. Welfare Economics, Uncertainty, and Market Institutions
A conventional competitive benchmark presumes that agents can compare available commodities, contracts can specify important contingencies, and market prices convey socially relevant marginal costs. Medical care violates these presumptions in structured ways. Patients cannot predict precisely when they will fall ill, the efficacy of treatment is uncertain, physicians know substantially more than patients, and emergency decisions often allow little time for price search or bargaining. The 1963 analysis of medical uncertainty linked these features to insurance, trust, professional norms, and the development of organizational substitutes for missing markets.
A Pareto-efficient allocation is one in which no feasible reallocation makes one person better off without making someone else worse off. This is a limited criterion: it does not select among efficient allocations with profoundly different distributions of health or wealth. If health risks are uninsurable, informational contracts incomplete, or infectious disease externalities unpriced, a competitive equilibrium can fail to achieve even this efficiency criterion. The resulting institutions include licensure, nonprofit organizations, public finance, physician ethics, quality monitoring, and collective insurance. Each can alleviate particular failures while introducing governance costs and incentive problems.
For a risk-averse household, uncertain future medical bills reduce expected utility even before illness occurs. A contract that pools that risk creates value beyond any subsequent change in health. Conversely, insurers and providers can respond to subsidies and reimbursement in ways that alter prices, treatment volumes, and selection. The relevant welfare accounting must measure gains from risk protection, quality changes, administrative costs, taxation, behavioral responses, and the distribution of each consequence. The Anatomy of Health Insurance develops the joint logic of risk sharing and behavioral incentives.
5. Health Capital and the Household Production of Health
In the original health-capital formulation, health is a durable state that yields healthy time and is affected by investment and depreciation. A simplified stock equation is , where is health capital at the start of period , is its depreciation rate, and is effective investment. The expression is an accounting representation of the model, not a clinical equation applicable to individual patients. Investment may involve medical services, nutrition, exercise, preventive behavior, knowledge, and household time. The transformation from inputs to health outcomes depends on technology, baseline condition, preferences, and circumstances.
Individuals may demand health for its direct value and for the healthy time it makes available for work, leisure, and caregiving. The shadow price of health depends on service prices, time costs, depreciation, productivity of investment, and the opportunity cost of capital. Education may raise the productivity of health production, but the causal direction between education and health must be estimated rather than assumed. Severe illness changes constraints and the feasible set of inputs, while low income may turn a relatively modest service fee into an effective prohibition on care.
A health-capital framework makes policy mechanisms visible. Subsidizing vaccines changes the price of a potential input; improving drinking water changes the production environment; reducing travel time changes the time cost of clinical access; and income support can ease several constraints simultaneously. The framework does not imply that all health outcomes are controllable by individual effort. Its contribution is to organize intertemporal choices under constraints while leaving room for biology, externalities, institutions, and unequal opportunity.
6. Demand for Care, Prices, and Elasticities
Demand for medical care is derived from anticipated health improvement, information, insurance coverage, nonmedical costs, and urgency. Price is often fragmented into premiums, deductibles, coinsurance, copayments, balance bills, travel expenses, waiting time, and foregone earnings. A patient facing a low point-of-service charge may still face a high effective price if treatment requires repeated travel or long unpaid absence. Conversely, insured reimbursement can weaken the direct relationship between the marginal social resource cost and the amount paid by a patient.
For a conventional elasticity, . This measures a proportional change in utilization associated with a marginal proportional price change, holding modeled conditions constant. The RAND randomized demand study reported an approximate medical expenditure price elasticity around -0.2 in its experimental setting and a substantial difference between zero cost sharing and catastrophic coverage. That estimate is context-specific. It does not imply equal responsiveness for every medication, emergency episode, patient income group, or health system, nor does it directly measure the welfare effect of cost sharing.
A demand reduction may eliminate low-value treatments or suppress clinically important care. Differentiating the two requires information about marginal benefit, not just the number of claims. The study of cost sharing among elderly beneficiaries found increased hospitalization as an offset in a particular setting, illustrating that reductions in one type of spending can shift costs into another payer or service. Demand estimation therefore needs total resource accounting, meaningful health outcomes, patient heterogeneity, and behavioral mechanisms.
7. Insurance, Risk Pooling, and Welfare
Health insurance transforms uncertain financial losses into more predictable payments and contractual rights. If individual medical expenses are imperfectly correlated, a sufficiently diversified risk pool can make the aggregate cost of claims more predictable than each participant's cost. The economic value of coverage includes variance reduction and the capacity to receive necessary services when liquidity would otherwise be insufficient. For concave utility , insurance can raise expected utility even when its premium includes administrative loading, provided risk reduction outweighs the loading and other distortions.
A stylized example clarifies the distinction. Suppose an individual has a 10% probability of a medical bill of $10,000. The actuarially expected expense is $1,000. Insurance priced at $1,100 includes $100 of loading. A risk-neutral, fully liquid consumer compares expected expenditure with premium and would normally reject the contract on price alone. A risk-averse household may rationally pay the loading to reduce a large contingent loss. The illustration assumes a known probability, no moral hazard, enforceable benefits, and no insurer insolvency; real contracts require additional considerations.
The distribution of willingness to insure depends on wealth, health risk, and existing protection. Medicare's early effects on catastrophic spending in the historical insurance study show why protection against financial loss is a separate welfare endpoint. A policy evaluation that checks mortality alone misses important insurance benefits. Equally, expanding insurance without addressing provider supply, clinical quality, or administrative barriers may fail to achieve anticipated health gains. The assessment must ask which risk has been shifted, to whom, and at what economic cost.
8. Adverse Selection, Moral Hazard, and Contract Design
Adverse selection arises when potential buyers know risk-relevant information that insurers do not, or when risk types sort systematically across available plans. High-risk individuals may value comprehensive policies more strongly, causing a plan's average claims cost to rise with enrollment composition. Risk adjustment, compulsory participation, enrollment rules, and public subsidies change the resulting equilibrium. Selection should be distinguished from risk differences that are fully priced or contractually observable. Market-level inference requires measuring sorting and insurer responses, not simply observing that sick people buy more insurance.
Moral hazard describes changes in actions induced by the allocation of risk. Ex post moral hazard can increase service use when insured patients face lower marginal prices; ex ante moral hazard concerns preventive behavior before illness. The term is an analytical description, not a moral judgment about patients. Health insurance contract theory studies the tradeoff between valuable protection and incentives for additional utilization, including supplier-induced demand. Optimal cost sharing depends on the marginal health value of treatment, the marginal resource cost, income effects, and the capacity to target subsidies to high-value services.
Contracts are also incomplete. Coverage exclusions, prior authorization, networks, risk corridors, stop-loss arrangements, and appeals are designed to control behavior and financial exposure but introduce transaction costs. A coherent contract-design assessment must evaluate who carries residual risk: the insured household, provider, insurer, employer, or state. Financial protection, utilization, quality, and distribution may move in different directions when a contract changes. The principal empirical question is how its features alter behavior and realized outcomes within a specified environment.
9. Evidence from Randomized Health Insurance Reforms
Experimental evidence provides unusually strong leverage on causal claims when assignment is genuinely random and analysis respects the design. The RAND Health Insurance Experiment varied patient cost sharing and documented a consequential utilization response. Its findings concern the populations, time, benefit designs, and medical technology observed in the study; transferring an elasticity to a different health system requires separate justification.
The Oregon Medicaid lottery provides another informative sequence. The first-year insurance study found more medical utilization, reduced out-of-pocket payments and medical debt, and improved self-reported outcomes among lottery winners. The two-year clinical examination reported increased detection and management of diabetes, lower rates of depression, reduced financial strain, and no statistically significant changes in several measured physical endpoints within the observed period. A null finding on specific measured endpoints should not be rewritten as proof of zero health effect; confidence intervals, power, duration, and the set of measured outcomes delimit inference.
Moreover, the emergency-department follow-up found that Medicaid increased emergency visits in the study environment. This result challenges the assumption that insurance necessarily substitutes office visits for emergency care in the short run. Read together, the Oregon papers show that access, utilization, mental health, financial protection, diagnoses, and physiological outcomes are distinct causal channels. Scientific synthesis must retain these distinctions instead of selecting a single result to support a predetermined policy position.
10. Provider Agency, Professional Knowledge, and Quality
Medical providers are knowledgeable agents acting for patients who face uncertainty, urgency, and limits on diagnostic interpretation. Agency is imperfect because compensation may depend on procedure volume, budget targets, patient satisfaction, outcomes, or contractual rules, each an incomplete measure of social value. Physicians also face professional obligations, legal constraints, practice norms, peer review, and uncertainty about treatment effectiveness. The account of asymmetric medical knowledge emphasizes how trust and professional conduct emerge within this environment.
Quality is multidimensional: effective diagnosis, appropriate treatment, clinical safety, continuity, accessibility, respectful communication, and long-term outcomes. Quantitative indicators sometimes reward activities that are easy to count rather than care that is valuable to patients. Risk adjustment is necessary when provider populations differ in severity, but it can conceal real disparities if adjustment variables encode preventable disadvantage. Quality measurement must specify the causal pathway between an observed performance indicator and the desired patient outcome.
Provider behavior is sensitive to both internal motivation and external incentives. A fee increase can expand service supply yet also generate additional low-value utilization; a budget cap can restrain waste yet produce delayed access. Neither mechanism can be evaluated solely from a price schedule. The appropriate empirical unit may be the patient episode, practice, hospital, integrated network, or regional market. Research on provider competition shows that quality and treatment decisions interact with institutional organization and bargaining power.
11. Hospitals, Market Structure, and Competition
Hospitals are multiproduct organizations with fixed costs, emergency obligations, specialized labor, reputational capital, complex internal governance, and potentially strong local market power. Their costs vary with case mix, occupancy, clinical staffing, teaching activity, and service breadth. Economies of scale and scope can make some consolidation efficient, while concentration can also weaken price discipline. Economic analysis must separate hospital ownership type from actual competitive conditions and distinguish prices negotiated by payers from resource costs incurred in production.
Industrial organization examines entry barriers, mergers, insurer networks, bargaining, patient choice, hospital differentiation, referral patterns, and quality competition. The Industrial Organization of Health-Care Markets reviews how these mechanisms affect price, quality, and treatment decisions. The hospital price variation study demonstrates the importance of negotiated prices for private insurance spending in the United States. A high hospital bill can reflect a high transaction price with no equivalent increase in treatment volume or health benefit. Comparing billed charges, negotiated prices, payments, and economic costs without a common definition produces invalid conclusions.
The relevant geographic market depends on travel constraints, emergency versus elective services, referral networks, and patient willingness to switch providers. Competition can improve incentives under some contracting arrangements but may be limited by information asymmetry and selective network designs. Antitrust policy, certificate-of-need rules, facility regulation, and public procurement alter entry and bargaining conditions. A mature account asks when concentration improves coordination, when it reduces choice, and how observed outcomes depend on payer power and patient access.
12. Payment Systems, Provider Incentives, and Capacity
Provider payment determines which activities generate revenue and who bears financial risk. Fee-for-service remuneration pays for identifiable services; capitation provides a fixed amount per enrolled person; salary compensates time or role; global budgets constrain aggregate payments; diagnosis-related groups and bundled payments compensate episodes with defined classifications. Each arrangement creates incentives around selection, service intensity, coding, preventive investment, and the shifting of patients across settings. Hybrid contracts often use quality adjustments, risk adjustment, and outlier protection to address the vulnerabilities of any single method.
Under fee-for-service, marginal revenue from an additional reimbursable procedure may exceed its resource cost, encouraging supply when demand is elastic to professional recommendations. Under capitation, providers retain savings from reducing costs but can face incentives to avoid complex patients unless risk adjustment and quality monitoring are adequate. Under a global budget, spending is more predictable for a payer, while capacity and waiting time become central indicators. These are incentive mechanisms, not universal predictions. Provider-market research emphasizes that actual behavior depends on competition, information, and institutional context.
Capacity planning connects payments with the physical production function. Surgical theaters, diagnostic equipment, beds, community clinics, staffing, and referral systems have complementary input relationships. Adding an expensive scanner without sufficient technicians does not create proportional diagnostic throughput; expanding insurance without provider capacity can produce queues. Sustainable resource allocation requires both an accounting budget and operational constraints. Policy evaluation should measure patient outcomes, waiting times, provider solvency, labor conditions, and the distribution of effective access along with nominal expenditure.
13. Pharmaceutical Markets, Patents, and Therapeutic Competition
Pharmaceutical markets combine high upfront research costs, uncertain clinical success, costly regulatory evidence, manufacturing scale, and a legal period of exclusivity with a comparatively low marginal cost for producing many established medicines. The privately profitable research agenda depends on expected market size, therapeutic substitutes, payer reimbursement, patent duration, and the probability that a product will reach clinical use. Evidence on market size and drug innovation links shifts in potential demand to pharmaceutical development, illuminating the endogenous direction of innovation. This association concerns specific market incentives and does not make patient need identical to commercial demand.
Price formation differs between on-patent brands, therapeutically differentiated competitors, small-molecule generics, and biologics with biosimilar pathways. A list price may differ substantially from a net price after confidential rebates or negotiated discounts. The Medicare Part D price analysis examines how expanded insurance and intermediary bargaining changed pharmaceutical prices and utilization. Its lesson is institutional: purchaser scale, formulary design, substitution and competitive conditions mediate the effect of coverage expansion on prices. A single observed posted price cannot describe the complete distribution of payments among patients, insurers, pharmacies, manufacturers, and public programs.
Patent protection, regulatory exclusivity, public research, procurement, prizes, subsidies, and advance commitments alter the reward to discovery. Policies that increase the affordability of current therapies may change incentives to produce future medicines, and policies favoring development can impose large present access costs. The efficiency question is intertemporal: which arrangements best align research incentives, clinical value, safe production, affordability, and equitable access across populations and generations? Comparative assessment must retain uncertainty about discovery and genuine therapeutic benefit, including the difference between surrogate endpoints and patient-important outcomes.
14. Prevention, Vaccination, and Public Health Externalities
Prevention changes the probability or severity of future disease. Vaccination, screening, environmental improvements, vector control, injury prevention, tobacco regulation, and infectious-disease surveillance have distinct technologies, target populations, and benefit horizons. Private willingness to pay can fall below social benefit when one person's prevention lowers exposure for others. Epidemiological spillovers also mean that benefits depend on coverage, contact patterns, pathogen characteristics, and timing. A program's marginal effect therefore changes as uptake and background risk change.
Prevention can be underprovided when benefits arrive later, when consumers lack reliable information, or when the eventual beneficiaries differ from current decision-makers. Yet prevention does not automatically save money. A preventive intervention is cost-saving only if its implementation cost is lower than the future resources it avoids, measured over a consistent horizon. It can be highly cost-effective while increasing total expenditure because it extends life or produces valuable health gains. The distinction between expenditure savings and welfare gains is essential.
The analysis of preventives versus treatments examines how demand and innovation incentives differ when a product is purchased before or after illness. This helps explain why investment incentives can diverge even when prevention has substantial social value. Public procurement, vaccination programs, health communication, and risk-based screening may remedy selected underinvestment. Their evaluation requires identifying direct effects, indirect protection, adverse events, behavior change, administrative costs, and distributional patterns. For screening, false positives and overtreatment enter the welfare balance along with earlier detection.
15. Population Health, Epidemiology, and Burden of Disease
Health economics uses epidemiological measures to describe the health consequences of economic choices. Incidence measures new cases over a period; prevalence records existing cases; mortality rates, survival curves, cause-specific risks, and disability measures describe different dimensions of burden. Comparisons should specify denominators, age structure, exposure windows, and methods used to assign causes. Crude mortality can rise because populations age even while age-specific risks decline. An economic explanation of this shift requires demographic standardization before attributing it to healthcare system performance.
The Global Burden of Disease cause-of-death study provides harmonized estimates across countries and time while relying on modeled adjustments for incomplete vital registration and heterogeneous source quality. Such estimates are valuable for prioritization but should not be presented as direct census counts wherever they are modeled. Uncertainty intervals describe estimation precision under methodological assumptions, and local data may reveal differences hidden in national aggregates.
The historical mortality-development relationship established an influential descriptive association between longevity and income across countries and time. Improvements in public health technology, infrastructure, diffusion of medical knowledge, and institutional capacity can shift that relationship. The relationship is not a universal causal coefficient: income may influence health and health may influence income, while sanitation, education, public policy, and demographic transitions affect both. Cost-effective priorities emerge by combining burden measurement with intervention efficacy, feasibility, opportunity cost, and fairness rather than simply ranking causes by deaths or spending.
16. Health Inequality, Need, Equity, and Distribution
Equity assessments begin by specifying which differences are ethically and economically relevant. Equal health, equal access for equal need, equal treatment for equal need, equal expenditure, and equal financial burden are different objectives. The foundational equity analysis clarifies why these objectives may conflict. For example, equal spending per person may leave individuals with greater medical need much worse off, while identical health outcomes may require very unequal resource inputs. Horizontal equity concerns comparable treatment of people in comparable circumstances; vertical equity concerns the appropriate differentiated treatment of those in different circumstances.
Income, education, housing, occupational hazards, discrimination, neighborhood exposures, and political institutions shape health production and healthcare access. The commission report on social determinants emphasizes that health gradients arise through conditions of daily life, labor, and unequal distribution of resources. These gradients interact with health-system financing: user charges may deter necessary treatment among low-income households more strongly than among affluent households, even when nominal prices are identical.
Equity also requires transparent choice of population weights and comparison groups. A budget transfer can improve average health yet widen the health gap between groups; a geographically targeted program can narrow a gap yet yield fewer aggregate life years than another feasible investment. The distributional cost-effectiveness tutorial formalizes how analysts can represent such tradeoffs, while recognizing that empirical estimates of group-specific effects and social preferences contain uncertainty. Scientific analysis should display alternative distributional assumptions and their consequences rather than embed one set of weights invisibly within the result.
17. Health Financing, Taxation, and Risk Pooling
Health financing has three connected functions: raising revenues, pooling resources and risks, and purchasing services. Revenue can derive from general taxation, payroll contributions, insurance premiums, user payments, donor funds, and earmarked levies. Financing design determines whose income supports care, how resources move between healthy and sick people, and whether eligibility depends on employment, residence, income, age, or citizenship. The administrative form of a payer is less informative than the incidence of payments and the benefits actually received.
Pooling across people and across time can protect households against catastrophic spending. Fragmented pools may contain unequal benefits or competing reimbursement rates; integration may redistribute risks but require stronger governance and budget discipline. Economic incidence differs from statutory incidence: a payroll tax nominally paid by employers can affect wages, employment or prices, depending on labor-market adjustment. The health financing equity review explains why financing progressivity and the distribution of service delivery must be evaluated as separate dimensions.
A complete public-finance account compares the marginal cost of raising tax revenue with the health and insurance benefits financed by that revenue. It also examines evasion, labor supply, formal employment, fiscal capacity, and stabilization under economic shocks. Public funding can improve risk protection, while uncontrolled purchasing may reward high prices or ineffective care. Revenue collection, pooling, and strategic purchasing therefore have to be studied as an integrated fiscal arrangement, with explicit attention to resource constraints and accountable allocation.
18. Universal Coverage, Financial Protection, and Effective Access
Universal health coverage requires a joint assessment of service access and financial protection. Legal enrollment is one input; sufficient staff, geographic access, medicines, diagnostics, timely appointments, clinical quality, and acceptable out-of-pocket costs determine the realized value of coverage. A nominal insurance card does not establish that a clinically indicated service was delivered. Likewise, a health system may provide relatively broad basic services while still exposing some households to severe expenditure risk.
The 2025 universal coverage monitoring report draws on updated indicators to characterize service coverage and financial hardship worldwide. The report estimates a global service-coverage index of 71 out of 100 in 2023 and reports that a substantial share of the global population still faces financial hardship from out-of-pocket payments. These measures employ defined thresholds and modeling methods: they are measures of coverage and financial hardship, not direct estimates of the welfare loss that a given reform would remove. Comparability depends on survey quality and changes in definitions.
Effective access can improve through strengthened primary care, lower user charges, predictable medicine supplies, referral design, improved disability access, and geographically responsive capacity. Each instrument has a budget cost and an opportunity cost. Policy analysis should report service utilization, unmet need, care quality, household financial exposure, distributional effects, and fiscal sustainability as jointly relevant outcomes. Evidence on Oregon and Medicare illustrates that valuable coverage effects can appear in economic security before or alongside measurable clinical changes.
19. Health Technology Assessment and Economic Evaluation
Health technology assessment examines the clinical, economic, organizational, ethical and implementation consequences of medicines, devices, procedures, diagnostic strategies and service configurations. Economic evaluation makes the comparison of alternatives explicit. Cost-effectiveness analysis relates incremental resources to defined health effects; cost-utility analysis commonly uses quality-adjusted life years; cost-benefit analysis translates appropriately valued benefits and costs into monetary terms; cost-minimization is valid only under credible equivalence of relevant outcomes.
The foundations of cost-effectiveness analysis and Second Panel recommendations emphasize comparison against a relevant alternative, consistent perspective, time horizon, outcome measurement, sensitivity analysis and transparency. The incremental cost-effectiveness ratio is when the denominator is nonzero. If one intervention costs less and produces better outcomes than the comparator, it dominates. When the alternatives have heterogeneous health dimensions, the choice of summary outcome becomes a consequential value judgment.
The technology appraisal methods manual provides a specific institutional approach to evidence appraisal and committee judgment; its thresholds, discounting conventions, and modifiers belong to that jurisdiction and policy process. A cost-effectiveness threshold must be related to the opportunity cost of displaced care or to the relevant decision-maker's stated willingness to pay. Treating a published threshold as a universal constant would conceal differences in health budgets, prices, unmet need, and social priorities. The appropriate conclusion combines clinical evidence, uncertain long-term extrapolation, budget impact, and implementation feasibility.
20. Quality-Adjusted Life Years, Disability, and Value Measurement
A quality-adjusted life year combines duration with a preference-based health-state value under a specified valuation system. If health utility is and survival is represented over a time horizon , the undiscounted quantity is . With constant annual discount rate , discounted QALYs may be written under continuous discounting. The resulting statistic depends on how health states are described, whose preferences are elicited, and how uncertainty and comorbidity are represented.
Disability-adjusted life years combine years of life lost and years lived with disability in burden studies. A DALY is a measure of health loss; a QALY is a measure of preference-weighted health benefit. Their scales, construction, and interpretation differ. Measurement becomes especially challenging for mental health, disability, long-term care, pediatric conditions, and interventions whose benefits concern dignity, autonomy, or caregivers. A single number is useful for comparative allocation only when the underlying social value choices are explicit.
The reference-case recommendations call for describing benefits and costs beyond the healthcare sector rather than hiding them. A technology may affect labor-force participation, family caregiving, education or housing; whether such effects enter a particular perspective is a normative and methodological decision. Double counting occurs if the same benefit is included in both measured quality of life and a separate monetized productivity term without adjustment. Sound valuation records each channel, its unit, perspective, time horizon, and evidence source.
21. Uncertainty, Modeling, and Decision Thresholds
Economic evaluations project uncertain clinical and economic outcomes using decision trees, cohort state-transition models, microsimulation, survival models, and increasingly patient-level administrative data. The model is a structured representation of claims about disease progression, treatment effects, transitions, costs, and competing risks. Its validity depends on external clinical evidence, parameter estimation, transparent assumptions, and tests against independent observations. A complex model can offer a detailed account of uncertainty while still making invalid causal extrapolations.
Probabilistic sensitivity analysis assigns distributions to uncertain model parameters and propagates them through the decision calculation. Structural uncertainty addresses alternate disease states, functional forms, treatment pathways, and extrapolation assumptions; it cannot be reduced to uncertainty intervals for a fixed structure. Net monetary benefit is , where is the decision threshold, incremental health effect, and incremental cost. The sign of expected incremental net benefit can support a decision within the stated threshold and perspective; it does not prove universal social value.
The CHEERS 2022 reporting standards improve transparency by defining what should be reported about evaluation design, comparators, costs, outcomes, assumptions and uncertainty. Reporting completeness is distinct from empirical validity. Good practice includes model-code validation, extreme-value testing, calibration where justified, sensitivity to structural assumptions, and independent replication where feasible. Value-of-information analysis can estimate whether further research is worth funding when current uncertainty creates a material risk of choosing a suboptimal intervention.
22. Cost Accounting, Prices, and Health Expenditure
A health expenditure account records monetary flows; an economic cost estimate describes the opportunity value of resources used. Expenditures depend on provider prices, treatment volumes, wages, pharmaceutical costs, insurance administration, prevention, long-term care boundaries, capital formation, and the accounting rules applied. Charges, payments, expenditures, marginal costs, and full economic costs should not be conflated. International comparisons additionally require consistent currency conversion, purchasing-power adjustments, inflation treatment, and definitions of public and private spending.
The System of Health Accounts framework classifies spending by healthcare function, provider and financing arrangement. The global health expenditure database methodology describes how international health spending indicators are compiled and updated. These frameworks enable comparisons but cannot by themselves establish why one health system achieves better outcomes or whether every dollar recorded creates proportionate clinical value. Differences in population age, prices, disease burden and the definition of healthcare must be considered.
The WHO global spending report examines spending after the COVID-19 pandemic and documents pressures on public and private financing. Its cross-national evidence illustrates why high expenditure may coexist with uneven access and financial hardship. An empirical decomposition can write spending growth as a product of prices and quantities within well-defined service categories, while recognizing changes in intensity, case mix, technology and coding. Policy implications differ: lowering a monopoly price, eliminating an ineffective service, and reducing a necessary service each affect welfare differently even if recorded expenditure declines by the same amount.
23. Macroeconomics of Health and Human Development
Health enters macroeconomics through labor productivity, school attendance, human-capital accumulation, household saving, demographic composition, fiscal transfers and the stability of economic production. Better health may expand effective labor supply, support learning and reduce the time families spend managing avoidable illness. Economic growth can reciprocally improve nutrition, sanitation, housing and access to medical technology. This mutual feedback makes causal attribution challenging in comparisons of national income and life expectancy.
The Commission on Macroeconomics and Health report places population health among the productive foundations of development. The mortality and economic development study shows historically changing associations between incomes and mortality, underscoring the importance of technological and institutional changes that move the relationship over time. The direction and magnitude of macroeconomic returns vary by age structure, disease burden, employment opportunities, educational capacity, and quality of public institutions.
Macroeconomic evaluation should distinguish an intervention's real resource cost from expenditure that merely transfers purchasing power between agents. A health program that creates employment uses labor and capital that have alternative applications, even when the budget records the associated salaries as a benefit to local households. Long-run models should account for demographic adjustment, migration, public debt, and how additional years of healthy life affect both production and pension or care spending. Wider economic consequences deserve analysis without implying that people derive value from health only through their market productivity.
24. Labor Markets, Occupational Health, and Care Work
Illness and disability affect labor supply, wages, career accumulation, hours, absenteeism, and the allocation of unpaid work. Workers' health also depends on occupational exposures, job insecurity, shift schedules, access to leave, and the safety investment of employers. The causal relation is bidirectional: poor health can reduce earnings, while income and working conditions alter health risks. Labor economics helps separate these channels using longitudinal data, exogenous shocks, and carefully justified identification assumptions.
Informal care creates large economic value while often remaining outside standard measures of paid healthcare production. A caregiver may reduce employment hours, forego promotions, or experience health consequences. Valuing care at replacement wages or at foregone earnings answers different questions and can produce very different estimates. The health-sector and societal perspectives encourage explicit accounting for consequences that fall outside medical budgets. Such impact inventories should avoid assigning the same time cost twice through household expenditures and imputed labor values.
Employer-provided health insurance can affect job mobility, compensation bargaining, retirement timing, and worker sorting. Occupational health rules modify both injury incidence and production costs. Equity analysis must recognize unpaid care arrangements, migrant labor, precarious employment, and unequal exposure to hazards. An efficient health policy may be financed through the health budget yet generate substantial labor-market effects; scientific evaluation should trace those effects rather than assuming they belong to a wholly separate discipline.
25. Aging, Long-Term Care, and Life-Course Allocation
Population aging changes both the need for care and the fiscal structure of health systems. The demand for treatment and long-term support depends on disease prevalence, functional limitations, household structure, technology, clinical practice, and the degree to which additional years of life are spent in good health. Age alone is an incomplete indicator of expected cost: proximity to death, multimorbidity, frailty, and institutional care needs can matter substantially. Demographic projections therefore require models of health states, survival, service intensity, and changing informal care capacity.
Long-term care occupies the intersection of healthcare, housing, disability policy, social insurance, and family economics. Assistance with daily living may be delivered by households, paid home-care workers, community services or residential facilities. Different arrangements transfer costs between public budgets and private households, often without changing the underlying resource use proportionately. Underfunded community care may shift burdens onto unpaid caregivers, while unnecessary institutionalization can reduce autonomy and consume scarce capacity. The economic comparison must incorporate quality of life, caregiver time, workforce availability, and continuity of care.
Intergenerational redistribution is central to financing. Pay-as-you-go arrangements allocate current contributions to current beneficiaries; funded mechanisms accumulate assets for future claims; hybrids combine transfers and savings. Their sustainability depends on demographics, taxation, real wages, longevity, investment outcomes, and benefit design. A life-course perspective asks how early-life prevention affects chronic illness, how caregiving obligations affect employment, and how late-life care burdens fall across social groups. It also asks whose time and welfare count when care is provided outside formal institutions.
26. Mental Health, Behavioral Economics, and Patient Choice
Mental health changes subjective well-being, functional capacity, economic participation, family relationships, and demand for medical services. Disorders often interact with chronic physical conditions and may complicate treatment adherence. Economic measurement is especially sensitive to how patients report quality of life, how conditions are diagnosed, and whether observed healthcare utilization captures unmet need. Social stigma, provider shortages, information costs, insurance limitations, and the difficulty of forecasting future symptoms can produce persistent gaps between clinically beneficial treatment and actual use.
Behavioral economics examines present bias, limited attention, framing, default effects, beliefs about treatment, and trust. These mechanisms matter for vaccination appointments, medication adherence, screening, dietary change, and insurance plan selection. Behavioral interventions should be evaluated against a coherent welfare criterion: increasing adherence is not beneficial when a treatment is unnecessary or poorly tolerated. More information can change choices without removing structural barriers such as transport, income, childcare, or provider availability.
The Oregon clinical outcomes study found lower depression prevalence under Medicaid coverage within its measured context, alongside greater use of care and better financial security. Its evidence supports the existence of meaningful nonphysical outcomes while retaining uncertainty about other health measures. The midlife mortality and morbidity study demonstrates that population health can deteriorate within affluent settings and that economic and social gradients warrant disaggregated analysis. A complete mental-health economy includes prevention, crisis services, continuity of treatment, community support, informal care, and the broader environments influencing illness.
27. Global Health, Development Assistance, and Resource Constraints
Global health economics studies how international inequality, disease ecology, national fiscal capacity, migration, supply chains, aid institutions, and medical knowledge shape health opportunities. Financing conditions in low-income countries differ from those in wealthy economies because tax bases, administrative systems, insurance reach, workforce density, and access to medicines can be sharply constrained. The economic opportunity cost of a health budget dollar also differs when its next-best use may be basic sanitation, maternal care, vaccination, tuberculosis treatment, or emergency capacity.
International assistance can expand funding, transfer technology, support surveillance, and finance cross-border public goods. Its effectiveness depends on procurement integrity, predictability, complementary domestic capacity, and alignment with legitimate local priorities. Vertical programs focused on one disease may achieve measurable benefits yet compete for the same nurses, laboratories, and distribution networks required by routine care. The WHO health-system performance report emphasizes broader system goals, while the health and development assessment provides an early framework for considering health investment in economic development.
The global coverage monitoring framework shows that progress in service coverage and financial protection must be monitored jointly. Countries with similar income levels can differ in health outcomes because institutions, infrastructure, social conditions, and public priorities differ. Comparative assessments should avoid using national averages alone to rank program effectiveness; data coverage, conflict, migration, age composition, and within-country inequalities materially influence observed indicators. The objective is to identify feasible interventions that generate the greatest sustainable improvement under actual local constraints.
28. Infectious Disease, Epidemics, and Health Security
Infectious diseases generate dynamic externalities because one person's infection can raise exposure for others. The effects of vaccination, testing, isolation, ventilation, tracing, treatment, and information campaigns depend on transmission networks, pathogen biology, behavior, seasonality, and health-system capacity. An economic model of infectious disease must treat the epidemiological state as endogenous to choices: perceived risk changes mobility and contact, while policy changes both transmission and economic activity. Static estimates of intervention cost may miss these feedback effects.
Epidemic policy evaluates mortality, morbidity, long-term disability, lost schooling, forgone production, household security, mental health, and fiscal responses. The appropriate counterfactual matters: a comparison with unrestricted pre-epidemic economic activity can exaggerate the cost of protective measures if people would voluntarily reduce contacts under serious infection risk. The relevant comparison is between feasible epidemic paths under specified information and institutional constraints, with uncertainty about infection dynamics reported explicitly.
International surveillance, pathogen sequencing, vaccine research, and coordinated procurement have public-good characteristics because the benefits cross national borders. Private markets may underinvest when innovators cannot capture the full social return to early detection or platform readiness. Conversely, emergency procurement can create risks of waste, contract opacity and distributional exclusion. A robust health-security framework places infection dynamics, fiscal response, procurement incentives, scientific uncertainty, and international cooperation within one consistent evaluation rather than treating epidemic control as solely a hospital-capacity problem.
29. Environmental Exposure, Climate Change, and Health Economics
Environmental and occupational exposures alter morbidity, mortality, birth outcomes, mental health, and healthcare demand. Air pollution, unsafe water, heat, flooding, toxic substances, and extreme weather may affect health through different causal pathways and exposure durations. Market prices often omit damages borne by bystanders and future generations, creating a role for environmental regulation and public investment. Estimating social benefits requires translating exposure changes into credible health-response functions and then into outcomes valued under a transparent welfare framework.
Exposure assessment must account for geography, season, migration, baseline disease, age, socioeconomic status, and adaptation. An observed difference between highly polluted and cleaner areas may reflect economic selection as well as pollution damage. Causal designs exploit natural experiments, regulatory discontinuities, wind or geographic variation, and panel measurements, but their assumptions should be tested. Economic valuation must keep mortality-risk changes, illness costs, subjective welfare, and productivity channels separate to avoid double counting.
The social-determinants report identifies living conditions as a central driver of health inequality. The review of health and economic inequality further shows why statistical associations between income, inequality, and health require careful causal interpretation. Climate adaptation can include urban cooling, resilient clinics, disease surveillance, water infrastructure, and emergency planning. Mitigation policies may produce nearer-term health co-benefits from cleaner air, even when their primary purpose is long-run emissions reduction. The allocation question involves timing, risk, irreversibility, and the distribution of exposure. Discounting and uncertainty strongly affect comparisons of present intervention costs with distant health consequences.
30. Digital Health, Data, and Artificial Intelligence
Digital health technologies include electronic health records, telemedicine, clinical decision support, wearables, patient portals, remote monitoring, predictive algorithms and automation of administrative workflows. Their economic value depends on effects on clinical decisions, patient outcomes, provider time, access, diagnostic error, and total system cost. A technology that accelerates documentation without improving care may be valuable through saved labor; an algorithm that generates more referrals may increase expenditures without corresponding benefits. Evaluation must specify the intended decision, comparison process, and realized effect on patient welfare.
Health data are simultaneously productive inputs and sensitive personal information. Interoperability can reduce duplication, improve continuity of care, and support research, but data transfer raises governance, privacy, cybersecurity, and consent problems. Ownership arrangements, vendor contracts, switching costs, network effects, and platform concentration affect adoption and bargaining. An evaluation of an electronic record system must account for training, workflow disruption, maintenance, infrastructure and the possibility that efficiency gains arrive only after costly reorganization.
Artificial intelligence can generate predictions that change triage, diagnosis, resource scheduling and discovery. Predictive accuracy is insufficient by itself: decision thresholds, prevalence shifts, subgroup calibration, clinical accountability, and downstream treatment capacity determine practical consequences. An algorithm may be statistically accurate yet economically harmful if its use redirects scarce care away from patients with greater marginal benefit. The health economic reporting principles and the external-validity analysis reinforce the need for explicit comparators, context and outcome assessment; deployment evaluations should add monitoring of dataset shift, distributional effects, security and human oversight.
31. Empirical Identification: Experiments and Quasi-Experiments
Causal health economics asks what would have happened to the same person, practice, community, or system under a different policy. Because only one treatment state is observed for each unit at a given time, identification requires assignment mechanisms or assumptions that connect observed outcomes with credible counterfactuals. Randomized trials can identify average effects within their study design, while instrumental variables, regression discontinuity, difference-in-differences, interrupted time series and synthetic controls rely on different exclusion, continuity, trend or comparability conditions.
The econometric identification handbook clarifies how selection and omitted variables threaten causal interpretation. In a randomized insurance offer, assignment to eligibility can estimate an intention-to-treat effect; the effect of actual insurance coverage among compliers requires additional instrumental-variable conditions. The Oregon lottery study exemplifies this distinction. An estimated effect must specify its population, treatment, period, and outcome: a hospital-level average price response is not automatically the effect on an individual patient's health.
Threats include endogenous treatment adoption, anticipation effects, migration, spillovers, changing coding practices, and attrition correlated with outcomes. Difference-in-differences designs require defensible assumptions about untreated trends; instrumental variables require an exclusion restriction and a meaningful first stage. Researchers should predefine estimands, inspect baseline comparability, use appropriate clustering, report uncertainty, and distinguish statistical significance from clinical or economic significance. A result with a narrow standard error can still be biased by an invalid design.
32. External Validity, Heterogeneity, and Policy Transportability
An internally credible causal estimate addresses a specific intervention in a specific study environment. A policymaker often needs the effect in a different population, price system, provider network, or time period. The analysis of external validity in trials highlights how selection criteria, intervention delivery, adherence and care environments affect generalizability. Transportability is especially difficult in healthcare because treatment effectiveness, baseline risk, substitution possibilities, and costs can vary across demographic and institutional contexts.
Effect heterogeneity may be driven by age, disease severity, income, geography, provider quality, ethnicity, disability, insurance status, and availability of complementary services. Subgroup estimates should be interpreted according to prior specification, sample size, and multiple-testing risks. A policy may be cost-effective in a high-risk group yet ineffective in a low-risk group. A positive average effect cannot establish benefit for every patient, just as an overall null estimate may conceal opposing subgroup effects.
Transporting evidence requires tracing mechanisms. Does an insurance reform work by lowering patient prices, expanding provider supply, or shifting financial risk? Are those mechanisms operative in the target system? Can the target setting deliver the intervention at the modeled scale? Scientific reports should distinguish observed treatment effects from scenario-based extrapolation and should make the conditions required for transfer visible. Robust policy guidance emerges from convergent evidence across methods, populations and institutions, with explicit attention to important differences.
33. Health-System Governance, Regulation, and Political Economy
Healthcare is governed by professional licensing, product safety regulation, payment contracts, competition rules, public procurement, insurance eligibility, health information law, and public budgeting. These institutions allocate authority and determine which costs and risks are visible to decision-makers. Regulation can correct information failures and externalities, yet it can also impose compliance costs, restrict entry, or create opportunities for incumbent influence. The welfare effect depends on the specific rule and market environment rather than on a general preference for more or less regulation.
Budget-making is political because benefits and costs accrue to different populations and organizations. Hospitals, clinicians, insurers, drug manufacturers, employers, patient groups, and taxpayers have divergent interests. Program entitlements can become durable while budgets for public-health prevention remain vulnerable because preventive benefits are dispersed, delayed or hard to attribute. Research on healthcare market organization demonstrates why price competition and provider behavior have to be assessed inside institutional arrangements. Economic evaluation should also consider legitimacy, accountability, evidence standards and practical administrative capacity.
The health-system performance framework treats responsiveness and the distribution of financial burden alongside population health. Governance quality enters economic analysis through trust, rule enforcement, purchasing integrity, quality monitoring and appeals. Sound reforms document expected gains, fiscal exposure, transition costs, distributional changes and mechanisms for revision when evidence changes. The appropriate question is whether governance aligns decisions with high-value care and fair risk allocation under the constraints the system actually faces.
34. Integrated Analytical Synthesis and Research Frontiers
The preceding evidence supports an integrated interpretation of the discipline. Health economics operates across four linked decision domains: the creation of health through living conditions and medical inputs; the allocation of uncertain financial risk; the organization of healthcare production and prices; and the collective selection of interventions under constrained budgets. These are analytical distinctions used here to organize established findings, rather than a newly proposed formal theory. Their connections explain why single-metric reform assessments are often inadequate.
First, expenditure is an ambiguous performance indicator. Spending growth may reflect more care, higher negotiated prices, better technology, improved survival, administrative waste, or unfavorable disease trends. A valid causal explanation identifies quantities, prices, quality and population composition. Second, financial protection is a legitimate outcome alongside health improvement. The Medicare financial protection analysis and Oregon experimental evidence demonstrate why an intervention's value cannot be summarized by a single short-run clinical endpoint.
Third, the same institutional reform may redistribute costs across budget holders while leaving total resources unchanged. Moving care from a public hospital to an unpaid family caregiver may reduce recorded government expenditure yet increase real social cost. Fourth, a highly favorable average cost-effectiveness ratio can coexist with severe inequity or implementation barriers. The distributional evaluation approach makes some of those tensions measurable, while the equity framework explains why competing fairness goals must be stated.
Fifth, uncertainty has multiple dimensions: causal uncertainty about program effects, statistical uncertainty about measured outcomes, structural uncertainty about long-term models, and institutional uncertainty about whether delivery systems will implement an intervention as intended. Research priorities consequently include cross-setting replication, high-quality longitudinal data, better measurement of patient-important outcomes, transparent procurement prices, and outcome studies of digital and artificial-intelligence tools. The international health indicators and health expenditure methodology provide comparative infrastructure, while clinical and social outcomes require additional linked evidence.
The discipline's mature research program integrates economics with epidemiology, biostatistics, medicine, demography, psychology, ethics, law, political science and environmental science. Interdisciplinary contributions must preserve the causal meaning and measurement units of each field. An epidemiological association is not an economic welfare estimate; a budget identity is not a causal effect; a social preference is not a laboratory measurement. Transparent links among these elements make economic analysis useful to science and institutions without claiming that one analytical vocabulary exhausts the value of human health.
35. Conclusion
Health economics investigates how societies produce health, finance illness-related risks, organize healthcare, and choose among competing uses of limited resources. Its scientific foundations include uncertainty and information, health capital, insurance theory, welfare economics, industrial organization, public finance, epidemiology, causal inference and economic evaluation. The historical work of Arrow, Grossman, Preston and later empirical researchers illustrates how the field expanded from medical care markets to an encompassing science of health and social allocation.
The empirical record establishes differentiated policy effects. Insurance can improve financial security and access while measured clinical results depend on baseline need, time horizon, provider capacity and outcome choice. Provider prices may drive expenditure independently of volume; prevention can deliver large health benefits without reducing net budgets; pharmaceuticals create intertemporal tradeoffs between innovation and present access. Economic evaluation compares incremental effects against real opportunity costs while distributional analysis exposes who gains, who pays and whose health remains underserved.
An appropriate scientific conclusion follows from these connections. Health-system performance should be assessed through a coherent set of measures that includes population health, patient welfare, clinical quality, effective access, financial protection, economic cost, equity, and long-run institutional capacity. Causal findings must retain their identified populations and assumptions, modeled projections must display uncertainty, and normative tradeoffs must be explicit. This synthesis organizes established health-economic knowledge and identifies research priorities; it does not institute a new theory, prescribe personal treatment, or assert original empirical estimates.
References
- Acemoglu, D., & Linn, J. (2004). Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics, 119(3), 1049-1090.
- Angrist, J. D., & Pischke, J.-S. (2009). Mostly Harmless Econometrics: An Empiricist's Companion. Princeton University Press.
- Arrow, K. J. (1963). Uncertainty and the Welfare Economics of Medical Care. American Economic Review, 53(5), 941-973.
- Asaria, M., Griffin, S., & Cookson, R. (2016). Distributional Cost-Effectiveness Analysis: A Tutorial. Medical Decision Making, 36(1), 8-19.
- Baicker, K., Taubman, S. L., Allen, H. L., et al. (2013). The Oregon Experiment - Effects of Medicaid on Clinical Outcomes. New England Journal of Medicine, 368, 1713-1722.
- Case, A., & Deaton, A. (2015). Rising Morbidity and Mortality in Midlife among White Non-Hispanic Americans in the 21st Century. Proceedings of the National Academy of Sciences, 112(49), 15078-15083.
- Chandra, A., Gruber, J., & McKnight, R. (2010). Patient Cost-Sharing and Hospitalization Offsets in the Elderly. American Economic Review, 100(1), 193-213.
- Cooper, Z., Craig, S. V., Gaynor, M., & Van Reenen, J. (2019). The Price Ain't Right? Hospital Prices and Health Spending on the Privately Insured. Quarterly Journal of Economics, 134(1), 51-107.
- Culyer, A. J., & Wagstaff, A. (1993). Equity and Equality in Health and Health Care. Journal of Health Economics, 12(4), 431-457.
- Cutler, D. M., & Zeckhauser, R. J. (2000). The Anatomy of Health Insurance. Handbook of Health Economics, 1A, 563-643.
- Deaton, A. (2003). Health, Inequality, and Economic Development. Journal of Economic Literature, 41(1), 113-158.
- Duggan, M., & Scott Morton, F. (2010). The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. American Economic Review, 100(1), 590-607.
- Finkelstein, A., & McKnight, R. (2008). What Did Medicare Do? The Initial Impact of Medicare on Mortality and Out of Pocket Medical Spending. Journal of Public Economics, 92(7), 1644-1668.
- Finkelstein, A., Taubman, S., Wright, B., Bernstein, M., Gruber, J., Newhouse, J. P., Allen, H., & Baicker, K. (2012). The Oregon Health Insurance Experiment: Evidence from the First Year. Quarterly Journal of Economics, 127(3), 1057-1106.
- Fuchs, V. R. (1998). Who Shall Live? Health, Economics, and Social Choice (expanded ed.). World Scientific (original work published 1974).
- GBD 2023 Causes of Death Collaborators (2025). Global Burden of 292 Causes of Death in 204 Countries and Territories and 660 Subnational Locations, 1990-2023. The Lancet, 406, 1811-1872.
- Gaynor, M., Ho, K., & Town, R. J. (2015). The Industrial Organization of Health-Care Markets. Journal of Economic Literature, 53(2), 235-284.
- Grossman, M. (1972). On the Concept of Health Capital and the Demand for Health. Journal of Political Economy, 80(2), 223-255.
- Husereau, D., Drummond, M., Augustovski, F., et al. (2022). Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement. BMJ, 376, e067975.
- Kremer, M., & Snyder, C. M. (2015). Preventives Versus Treatments. Quarterly Journal of Economics, 130(3), 1167-1239.
- Manning, W. G., Newhouse, J. P., Duan, N., Keeler, E. B., Leibowitz, A., & Marquis, M. S. (1987). Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. American Economic Review, 77(3), 251-277.
- National Institute for Health and Care Excellence (NICE) (2026). NICE Technology Appraisal and Highly Specialised Technologies Guidance: The Manual (PMG36, updated 2026). NICE process and methods.
- OECD, Eurostat, & World Health Organization (2017). A System of Health Accounts 2011: Revised Edition. World Health Organization.
- Organisation for Economic Co-operation and Development (OECD) (2025). Health at a Glance 2025: OECD Indicators. OECD Publishing.
- Preston, S. H. (1975). The Changing Relation between Mortality and Level of Economic Development. Population Studies, 29(2), 231-248.
- Rothwell, P. M. (2005). External Validity of Randomised Controlled Trials: To Whom Do the Results of This Trial Apply?. The Lancet, 365(9453), 82-93.
- Sanders, G. D., Neumann, P. J., Basu, A., et al. (2016). Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA, 316(10), 1093-1103.
- Taubman, S. L., Allen, H. L., Wright, B. J., Baicker, K., & Finkelstein, A. N. (2014). Medicaid Increases Emergency-Department Use: Evidence from Oregon's Health Insurance Experiment. Science, 343(6168), 263-268.
- WHO Commission on Macroeconomics and Health (2001). Macroeconomics and Health: Investing in Health for Economic Development. World Health Organization.
- WHO Commission on Social Determinants of Health (2008). Closing the Gap in a Generation: Health Equity through Action on the Social Determinants of Health. World Health Organization.
- Wagstaff, A., & van Doorslaer, E. (2000). Equity in Health Care Finance and Delivery. Handbook of Health Economics, 1B, 1803-1862.
- Weinstein, M. C., & Stason, W. B. (1977). Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. New England Journal of Medicine, 296, 716-721.
- World Health Organization (2000). The World Health Report 2000: Health Systems: Improving Performance. World Health Organization.
- World Health Organization (2024). Global Spending on Health: Emerging from the Pandemic. WHO Global Health Expenditure Report.
- World Health Organization (2025). Methodology for the Update of the Global Health Expenditure Database. WHO technical document.
- World Health Organization & World Bank (2025). Tracking Universal Health Coverage: 2025 Global Monitoring Report. WHO / World Bank, ISBN 9789240117808.